Cystic fibrosis (CF) is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe. It is estimated that over 70,000 people worldwide are living with CF, with more than 30,000 in the US alone, and approximately 1,000 new cases diagnosed each year1.
MRSA is becoming more common among the pathogenic bacteria that cause lung infections in CF patients, having a presence in about 25% of people with the disease2.
MRSA is resistant to multiple antibiotics - biofilms are thought to be involved and lung infections caused by the bacteria often become long-term3. MRSA produces several virulence factors and its presence in the respiratory tract is associated with significant lung damage and is a major cause of mortality. The ability to treat such MRSA infections effectively would therefore significantly help CF patients.
Destiny Pharma's lead compound, XF-73, is being prepared for Phase 3 clinical development to prevent post-surgical Staphylococcal infections. To date, XF-73 has demonstrated in vitro to be active against many of the world's most pathogenic bacteria as outlined in the WHO priority list4. XF-73 acts via an ultra-rapid action, which kills bacteria (including antibiotic resistant strains), leaving them unable to mount a resistance response, according to
Contact:
CEO
CFO
T: +44 (0)1273 704 440
E: pressoffice@destinypharma.com
Mary Clark
T: +44 (0) 203 922 0891
E: DestinyPharma@optimumcomms.com
finnCap Ltd
Nominated Advisor and Broker
Corporate Finance
ECM
T: +44 (0) 207 220 0500
T: +49-211-529252-12
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.
(C) 2022 Electronic News Publishing, source